Albumin Carrier Therapy Foundation

The Albumin Carrier Therapy Foundation is a non-profit research organization based in Freiburg, Germany, dedicated to advancing the science of albumin-mediated drug delivery. Founded by Prof. Dr. Felix Kratz, the foundation focuses on the development and optimization of the Albumin Carrier Therapy (ACT) platform for treating various forms of cancer. The ACT technology utilizes the natural transport properties of human serum albumin to deliver therapeutic agents, such as cytotoxics or peptides, specifically to tumor tissues. By binding to endogenous albumin in the bloodstream, these prodrugs benefit from the high metabolic demand and increased uptake of albumin by malignant cells. This targeted approach is designed to enhance the efficacy of anti-cancer treatments while significantly reducing the side effects associated with conventional chemotherapy. The foundation supports academic research, scientific publications, and international collaborations to further the clinical potential of albumin-binding drug candidates.